Kyowa Kirin Competitors and Similar CompaniesClear all

Kyowa Kirin's competitors and similar companies include Propanc Biopharma, Istari Oncology, Vascular Biogenics and Gracell.
Kyowa Kirin
Kyowa Kirin
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
Propanc Biopharma
Propanc Biopharma
Propanc Biopharma, Inc. is a development-stage healthcare company focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer.
Istari Oncology
Istari Oncology
Istari Oncology is a biotechnology company focused on immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a variety of tumors.
Vascular Biogenics
Vascular Biogenics
VBL Therapeutics is a biopharmaceutical company focused on the development of treatments for cancer.
Gracell
Gracell
Gracell Biotechnologies is a clinical-stage biotech company developing cell gene therapies for cancer.
Founding Date
Founding Date
2008
Founding Date
2007
Founding Date
2016
Founding Date
2000
Founding Date
2017
Type
Type
Public
Type
Public
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Tokyo, JP HQ
Sydney, AU
Shanghai, CN
Prague, CZ
Tampere, FI
Düsseldorf, DE
Hong Kong, HK
see more
Locations
Camberwell, AU HQ
Locations
Durham, US HQ
Morrisville, US
Chapel Hill, US
Locations
Modi'in-Maccabim-Re'ut, IL HQ
Locations
Suzhou, CN HQ
Employees
Employees
5,974
Employees
1
Employees
129% increase
Employees
7600% increase
Employees
314
Valuation ($)
Valuation ($)
9.3 b
Valuation ($)
44.3 k
Valuation ($)
N/A
Valuation ($)
12.1 m
Valuation ($)
989.9 m

Financial

Revenue (est.)
Revenue (est.)
¥442.2b (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$310k (FY, 2023)
Revenue (est.)
N/A
Cost of goods
Cost of goods
¥90.1b (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$197k (FY, 2023)
Cost of goods
N/A
Gross profit
Gross profit
¥368.9b (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Gross profit
$113k (FY, 2023)
Gross profit
N/A
Net income
Net income
¥81.2b (FY, 2023)
Net income
($2.7m) (FY, 2023)
Net income
N/A
Net income
($11.3m) (FY, 2023)
Net income
(¥607.5m) (FY, 2022)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 5.1m
Total funding raised
N/A
Total funding raised
$ 185m
For sources of this data, please see the company profile

View Company Profiles

Propanc Biopharma
HQ
Camberwell, AU
Employees
1

Propanc Biopharma, Inc. is a development-stage healthcare company focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer.

View company
Istari Oncology
HQ
Durham, US
Employees
12↑ 9% increase

Istari Oncology is a biotechnology company focused on immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a variety of tumors.

View company
Vascular Biogenics
HQ
Modi'in-Maccabim-Re'ut, IL
Employees
7

VBL Therapeutics is a biopharmaceutical company focused on the development of treatments for cancer.

View company
Gracell
HQ
Suzhou, CN
Employees
314

Gracell Biotechnologies is a clinical-stage biotech company developing cell gene therapies for cancer.

View company